ATAZANAVIR (BMS-232632) FOR INDIVIDUALS INFECTED BY HIV: AN EARLY ACCESS PROGRAM

BRISTOL MYERS SQUIBB COMPANY,0 个研究点目标入组 0 人开始时间: 2003年9月30日最近更新: 2023年9月4日

适应症

试验速览

暂无简介。

•1) Treatment failure, defined as resistance to ARV therapy, metabolic abnormalities (for example, hypercholesterolemia, hyperglyceridemia) or another problem of intolerance or of attachment and disability of the patient. to structure an effective alternative HAART regimen using other ARV agents available.
•2) be over 16 years of age (or the minimum age determined by local regulations or legal requirements).
•3) Negative pregnancy test for women with ability to conceive.
•4) Both women with the ability to conceive and men must
•Use an effective barrier method of contraception.
•5) Patients must provide their informed consent in writing.
•6) Baseline laboratory values measured in the 2 weeks prior to the administration of the study drugs should be normal (serum creatinine, liver enzymes (AST, ALT) and total serum bilirubin)

•1) Pregnant or lactating women.
•2) Active abuse of alcohol or substances sufficient, in the opinion of the Investigator, to prevent adequate adherence to the study treatment or to increase the risk of developing pancreatitis or chemical hepatitis.
•3) Concomitant use of contraindicated medications (eg, rifampin, St. John´s wort, certain drugs that are substrates of CYP3A4 at narrow therapeutic intervals)
•4) Presence of cardiomyopathy (due to any cause) or of any significant cardiovascular disease, such as unstable ischemic heart disease.
•5) Known antecedents of QTc interval prolongation (e.g. induced by medications, congenital or for other causes).

发起方